Would you like to learn more about immunotherapy use and trials in cancer and in palliative care?
Immunotherapy Symptoms Clinical Trials: a new paradigm forum
Palliative, supportive and cancer care professionals are invited to attend the VCCC and CST co-hosted Immunotherapy Symptoms Clinical Trials: a new paradigm forum to progress clinical trials concepts in this evolving oncology field, recognise achievements, celebrate success and make connections for future directions.
Palliative care progress and achievements
The VCCC Building Trial Group Capability Program initial investment is focused on developing the palliative care group as a key priority area. The group’s development and activities have been underway for more than 12 months; it is timely to celebrate progress and achievements.
Here is a program for the day
Registrations are now open for the palliative care sessions in the afternoon. Please note you will need to register for morning and afternoon sessions separately.
Another insightful article from Dr Ranjana Sriastava, a Melbourne medical oncologist and writer, encapsulates my recent experience as a palliative care doctor on the frontline between hope and dying in a cancer centre.
The anticipated miracles of cancers dissolving before our eyes are common enough for patients and doctors to push on with expensive, sometimes self-funded treatment (at great cost) in preference to the needed preparation by patient and family for dying. For a patient and family perspective, skip down to the comments after the article and read HugiHugo’s description of his wife’s last months while undergoing treatment.
A patient with widely disseminated and aggressive melanoma having immunotherapy grunted at me in frustration last month. “Listen,” he said, “they are all high-fiving over there in the oncology clinic. Why do you want to talk about end of life stuff? It’s really confusing.” Pretty appalled at the idea that we were giving the patient mixed messages, I was fortunate to be able to do a joint consultation with the patient’s medical oncologist to nut out our different perceptions. Unfortunately for the patient, his oncologist confirmed that the treatment was very unlikely to be a miracle and most patients in his situation would live less than a year. To say that the patient was shocked was an understatement. Had he not been referred to my team for symptom management, this conversation would have happened later – or never.
Evidence is emerging that outcomes of immunotherapy in patients with poor performance status are very unimpressive. Patients with poor performance status had been excluded from initial trials.
Where does the deficit in our communication of hope lie? Is it in the delivery by the doctor? The reception by the patient? A bit of both? How can we accurately respond to the portrayal of immunotherapy in the media and social media as a miracle cure, and allow for the possibility of benefit without downplaying the risks?